Valion Bio (VBIO) Other Non-Current Liabilities (2025 - 2026)
Valion Bio (VBIO) posted Other Non-Current Liabilities of $454000.0 for Q2 2026, up 55.48% on a QoQ basis from $292000.0 in Q4 2025.
Powered by 
Analysis
Valion Bio (VBIO) Other Non-Current Liabilities (2025 - 2026) Analysis & Trends
Valion Bio has reported Other Non-Current Liabilities for 2 years, with the latest figure at $454000.0 in Q2 2026.
- On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $454000.0 in Q2 2026; TTM through Jun 2026 was $454000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $292000.0, changed N/A from the prior year.
- Other Non-Current Liabilities was $454000.0 for Q2 2026 at Valion Bio, up from $292000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $454000.0 in Q2 2026, with the low at $292000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Valion Bio | 298,792.01 | -1.90 Mn | -45,000.00 |